Trial Profile
A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs LHW 090 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions; Pharmacokinetics
- Acronyms LHW090
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Oct 2018 Status changed from active, no longer recruiting to completed.
- 15 Oct 2018 Planned End Date changed from 10 Oct 2018 to 9 Oct 2018.
- 15 Oct 2018 Planned primary completion date changed from 10 Oct 2018 to 9 Oct 2018.